Impact of Frailty on the Benefits of Dual Pathway Inhibition for the Secondary Prevention of Cardiovascular Events in the COMPASS Randomised Trial-Reference-Cited by-同舟云学术

Impact of Frailty on the Benefits of Dual Pathway Inhibition for the Secondary Prevention of Cardiovascular Events in the COMPASS Randomised Trial

Published:2024-06 Issue: Volume: Page:
ISSN:0828-282X
Container-title:Canadian Journal of Cardiology
language:en
Short-container-title:Canadian Journal of Cardiology

Author:

Leong Darryl P.^ORCID,Bosch Jackie,Bhatt Deepak L.,Avezum Alvaro,Yuan Fei,Yusuf Salim,Eikelboom John W.

Funder

Bayer AG

Publisher

Elsevier BV

Reference28 articles.

1. Rivaroxaban with or without aspirin in stable cardiovascular disease;Eikelboom;N Engl J Med,2017

2. Frailty is independently associated with short-term outcomes for elderly patients with non–ST-segment elevation myocardial infarction;Ekerstad;Circulation,2011

3. Modified frailty index can be used to predict adverse outcomes and mortality after lower extremity bypass surgery;Ali;Ann Vasc Surg,2018

4. Frailty is associated with worse outcomes in non–ST-segment elevation acute coronary syndromes: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial;White;Eur Heart J Acute Cardiovasc Care,2016

5. Accumulation of deficits as a key risk factor for cardiovascular morbidity and mortality: a pooled analysis of 154 000 individuals;Farooqi;J Am Heart Assoc,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply to “Frailty may blunt the therapeutic efficacy and complication risk through multi-pronged mechanisms”;Canadian Journal of Cardiology;2024-08